A 4-gene signature associated with clinical outcome in high-grade gliomas

Clinical Cancer Research

Volumn 17, Issue 2, 2011, Pages 317-327

  De Tayrac, Marie ^a,b   Aubry, Marc ^a,b   Saïkali, Stephan ^b   Etcheverry, Amandine ^a,b   Surbled, Cyrille ^a   Guénot, Frédérique ^a   Galibert, Marie Dominique ^a,b   Hamlat, Abderrahmane ^b   Lesimple, Thierry ^c   Quillien, Véronique ^d   Menei, Philippe ^e   Mosser, Jean ^a,b  

^a UNIVERSITÉ DE RENNES 1   (France)

^b RENNES UNIVERSITY HOSPITAL   (France)

^c Clinical Research Unit   (France)

^d Eugene Marquis Comprehensive Cancer Center   (France)

^e Angers University Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER RISK; CANCER SURVIVAL; CHAF1B GENE; EDNRB GENE; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GLIOMA; HJURP GENE; HUMAN; IDH1 GENE; MAJOR CLINICAL STUDY; MALE; METHYLATION; MICROARRAY ANALYSIS; PDLIM4 GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; BRAIN NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; MALE; META-ANALYSIS AS TOPIC; MIDDLE AGED; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 79251469441     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1126     Document Type: Article

References (35)

1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
2. Louis DN. Molecular pathology of malignant gliomas. Annu Rev Pathol 2006;1:97-117.
3. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
4. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765-73.
5. Behin A, Hoang-Xuan K, Carpentier AF and Delattre JY. Primary brain tumors in adults. Lancet 2003;361:323-31.
6. Li A, Walling J, Ahn S, Kotliarov Y, Su Q, Quezado M, et al. Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res 2009;69:2091-9.
7. Petalidis LP, Oulas A, Backlund M, Wayland MT, Liu L, Plant K, et al. Improved grading and survival prediction of human astrocytic brain tumors by artificial neural network analysis of gene expression microarray data. Mol Cancer Ther 2008;7:1013-24.
8. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006;9:157-73.
9. Liang Y, Diehn M, Watson N, Bollen AW, Aldape KD, Nicholas MK, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci USA 2005;102:5814-9.
10. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, et al. Gene expression profiling of gliomas strongly predicts survival. Cancer Res 2004;64:6503-10.
11. Nutt CL, Mani DR, Betensky RA, Tamayo P, Cairncross JG, Ladd C, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-7.
12. Colman H, Aldape K. Molecular Predictors in Glioblastoma: toward Personalized Therapy. Arch Neurol 2008;65:877-83.
13. Hong F, Breitling R. A comparison of meta-analysis methods for detecting differentially expressed genes in microarray experiments. Bioinformatics 2008;24:374-82.
14. de Tayrac M, Etcheverry A, Aubry M, Saïkali S, Hamlat A, Quillien V, et al. Integrative genome-wide analysis reveals a robust genomic glioblastoma signature associated with copy number driving changes in gene expression. Genes Chromosomes Cancer 2009;48:55-68.
15. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
16. Dunn J, Baborie A, Alam F, Joyce K, Moxham M, Sibson R, et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 2009;101:124-31.
17. Sun L, Hui A-M, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell 2006;9:287-300.
18. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL and Chory J., et al. RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 2006;22:2825-7.
19. Breitling R, Armengaud P, Amtmann A and Herzyk P. Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 2004; 573:83-92.
20. de Tayrac M, Lé S, Aubry M, Mosser J, and Husson F. Simultaneous analysis of distinct Omics data sets with integration of biological knowledge: Multiple Factor Analysis approach. BMC Genomics 2009;10:32.
21. Curran WJ Jr, Scott CB, Horton J, Nelson JS, Weinstein AS, Fischbach AJ, et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 1993;85:704-10.
22. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837-45.
23. Hosmer DW Jr, Lemeshow S. Applied logistic regression. New York: John Wiley; 1989.
24. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, et al. A multigene predictor of outcome in glioblastoma. Neuro Oncol 2010;12:49-57.
25. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
26. Polo SE, Theocharis SE, Klijanienko J, Savignoni A, Asselain B, Vielh P, et al. Chromatin assembly factor-1, a marker of clinical value to distinguish quiescent from proliferating cells. Cancer Res 2004; 64:2371-81.
27. Staibano S, Mignogna C, Muzio LL, Mascolo M, Salvatore G, Di Benedetto M, et al. Chromatin assembly factor-1 (CAF-1)-mediated regulation of cell proliferation and DNA repair: a link with the biological behaviour of squamous cell carcinoma of the tongue?Histopathology 2007;50:911-9.
28. Boumber YA, Kondo Y, Chen X, Shen L, Gharibyan V, Konishi K, et al. RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis. Cancer Res 2007; 67:1997-2005.
29. Vanaja DK, Ballman KV, Morlan BW, Cheville JC, Neumann RM, Lieber MM, et al. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin Cancer Res 2006; 12:1128-36.
30. Chen M, Sinha M, Luxon BA, Bresnick AR and O'Connor KL. Integrin alpha6beta4 controls the expression of genes associated with cell motility, invasion, and metastasis, including S100A4/metastasin. J Biol Chem 2009; 284:1484-94.
31. Foltz DR, Jansen LE, Bailey AO, Yates JR 3rd, Bassett EA, Wood S, et al. Centromere-specific assembly of CENP-a nucleosomes is mediated by HJURP. Cell 2009;137:472-84.
32. Dunleavy EM, Roche D, Tagami H, Lacoste N, Ray-Gallet D, Nakamura Y, et al. HJURP is a cell-cycle-dependent maintenance and deposition factor of CENP-A at centromeres. Cell 2009; 137:485-97.
33. Kato T, Sato N, Hayama S, Yamabuki T, Ito T, Miyamoto M, et al. Activation of Holliday junction recognizing protein involved in the chromosomal stability and immortality of cancer cells. Cancer Res 2007;67:8544-53.
34. Valente V, Teixeira S, Neder L, Okamoto OK, Oba-Shinjo SM, Marie SK, et al. Selection of suitable housekeeping genes for expression analysis in glioblastoma using quantitative RT-PCR. BMC Mol Biol 2009;10:17.
35. Shirahata M, Oba S, Iwao-Koizumi K, Saito S, Ueno N, Oda M, et al. Using gene expression profiling to identify a prognostic molecular spectrum in gliomas. Cancer Sci 2009;100:165-7.